Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Cocrystal Pharma Inc

Current price
1.77 USD +0.041 USD (+2.36%)
Last closed 1.69 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 18 923 268 USD
Yield for 12 month -34.78 %
21.11.2021 - 28.11.2021

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington. Address: 19805 North Creek Parkway, Bothell, WA, United States, 98011


WallStreet Target Price


P/E ratio

Dividend Yield

Current Year

Last Year

+5 427 000 USD

Current Quarter

Last Quarter

Current Year

-241 600 USD

Last Year

-239 500 USD

Current Quarter

Last Quarter

Key Figures COCP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -19 798 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -31.94 %
PEG Ratio
Return On Equity TTM -48.31 %
Wall Street Target Price 9 USD
Revenue TTM 510 000 USD
Book Value 3.02 USD
Revenue Per Share TTM 0.006 USD
Dividend Share
Quarterly Revenue Growth YOY 26.9 %
Dividend Yield
Gross Profit TTM -8 794 000 USD
Earnings Share -1.97 USD
Diluted Eps TTM -1.97 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics COCP

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History COCP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:12
Payout Ratio
Last Split Date 11.10.2022
Dividend Date 24.01.2018

Stock Valuation COCP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 17.8912
Price Sales TTM 92.4548
Enterprise Value EBITDA 0.2731
Price Book MRQ 0.6066

Financials COCP

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators COCP

For 52 weeks

1.38 USD 3.29 USD
50 Day MA 1.8 USD
Shares Short Prior Month 5 294
200 Day MA 2.24 USD
Short Ratio 0.65
Shares Short 9 834
Short Percent 0.13 %